A new oral GLP-1 medication can help adults with obesity and type 2 diabetes lose more weight and improve their blood sugar levels compared to a placebo, according to findings from the ATTAIN-2 trial ...
Hosted on MSN
A new daily pill beat oral Ozempic for weight loss and blood sugar in a major diabetes trial
Eli Lilly’s once-daily oral pill orforglipron outperformed oral semaglutide in reducing blood sugar and body weight over 52 weeks in adults with type 2 diabetes, according to results from the ...
Obesity is a major risk factor for many leading causes of illness and death worldwide. Data are needed regarding the efficacy and safety of the nonpeptide glucagon-like peptide-1 (GLP-1) receptor ...
Credit: Novo Nordisk. Wegovy tablets offer a daily oral alternative to injections for weight reduction and reducing cardiovascular risk in eligible adult patients. The Wegovy tablet is now available ...
Please provide your email address to receive an email when new articles are posted on . Daily oral semaglutide was tied to more weight loss vs. placebo plus lifestyle interventions in people with ...
A new once-daily weight-loss pill called orforglipron delivered better weight loss and blood sugar improvements for people with type 2 diabetes than the leading oral semaglutide in a major clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results